Epsilogen
Latest round
- Series B
Last raised
- Aug 2024
Total raised
- $61M
Investors
- 8
About Epsilogen
a.a. Epsilogen is a developer of immunoglobulin E antibodies that are used for the treatment of solid tumors including greater potency, enhanced tumor access, and a long tissue half-life. As of January 2023, Tim Wilson is the CEO of the company. The company’s product line includes MOv18 IgE, which is in phase I clinical trial in folate receptor alpha-positive cancer patients; EPS 201 for the treatment of breast and gastric cancers; and IGEG-X. Epsilogen is developing IGEG platform technology based on combining the power of IgE (immunoglobulin E) and IgG (immunoglobulin G) antibody molecules. The company plans to use its proceeds from March 2022 to continue the clinical development of MOv18 IgE in platinum-resistant ovarian cancer and support further development of IgE-based antibody candidates to treat cancers.
Who invested in Epsilogen
8 investors across 3 rounds
See all investors in Epsilogen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Epsilogen
Who invested in Epsilogen?
Epsilogen has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Epsilogen raised?
Epsilogen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Epsilogen last raise money?
Epsilogen's most recent round on record is a Series B, in Aug 2024.
What does Epsilogen do?
Epsilogen is a biotechnology company.
Where is Epsilogen headquartered?
Epsilogen is headquartered in London, UK.
Which VCs invest in companies like Epsilogen?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Epsilogen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Epsilogen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.